0001225208-20-002600.txt : 20200218 0001225208-20-002600.hdr.sgml : 20200218 20200218160752 ACCESSION NUMBER: 0001225208-20-002600 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200214 FILED AS OF DATE: 20200218 DATE AS OF CHANGE: 20200218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ballinger Kevin J. CENTRAL INDEX KEY: 0001566080 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 20625347 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2020-02-14 0000885725 BOSTON SCIENTIFIC CORP BSX 0001566080 Ballinger Kevin J. 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP & Pres, Interven Cardio Common Stock 2020-02-14 4 A 0 27246.0000 0.0000 A 107331.0000 D Common Stock 2020-02-14 4 F 0 11463.0000 42.3100 D 95868.0000 D Common Stock 2020-02-15 4 M 0 3230.0000 0.0000 A 99098.0000 D Common Stock 2020-02-15 4 F 0 1473.0000 42.3100 D 97625.0000 D Deferred Stock Units 2020-02-15 4 M 0 3230.0000 0.0000 D 2023-02-15 Common Stock 3230.0000 9690.0000 D On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. /s/ Scott G. Hodgdon, Attorney-in-Fact 2020-02-18